NCCTG N0872 (Alliance): A randomized placebo-controlled phase II trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma (GBM)

2004 Background: Preclinical data indicate that Src kinase signaling is markedly upregulated at the invasive GBM front following administration of the anti-VEGF antibody bevacizumab (Bev). The broa...